- Plans to invest ₹800 crores to build robust manufacturing capacity in the next four years.
- Aims to make dialysis facilities accessible for End-Stage Renal Disease (ESRD) patients across the country.
Pune, June 11, 2025: Renalyx Health Systems Private Limited, a leading technology innovator in the renal care sector, has unveiled Renalyx – RXT 21, India’s first fully indigenous, Artificial Intelligence (AI) and cloud-enabled smart hemodialysis machine with remote monitoring and clinical connectivity. The machine starts at a price of ₹6.70 lakh, significantly lower than imported machines. Renalyx – RXT 21 is expected to make dialysis affordable and accessible to a larger population, bridging the demand-supply gap in kidney treatment in semi-urban and rural areas.
Developed and manufactured entirely in India, the Renalyx – RXT 21 machine utilizes the latest technology with a cloud-based tele-nephrology platform to ensure safety and quality care for kidney patients, especially those with End-Stage Renal Disease (ESRD) and related cardiovascular, pulmonary, and acute kidney injury issues.
With Renalyx – RXT 21, Renalyx becomes the sixth company globally and the first in India to produce advanced dialysis machines with European Union CE certification.
Renalyx plans to invest ₹800 crores over the next four years, aiming to build a production capacity of 5,000 machines by the end of FY 2025-26, and an additional capacity of 1,500 machines by FY 2027-28. The company also plans to produce indigenous consumables. To meet growing demand and support capacity expansion plans, the company has manufacturing facilities in Bengaluru and Mysuru in Karnataka, and Mumbai in Maharashtra.
The company is planning to raise funds through equity sale, based on strong interest from major Indian and international investors. Additionally, it will raise funds through debt and promoters will also invest capital. Renalyx also plans to go public in the next three years.
With initial deployments of these machines in Maharashtra and Karnataka, Renalyx, along with its partners, will rapidly distribute Renalyx – RXT 21 across India and also export to other countries. The company has successfully entered international markets, receiving orders from South Africa, the USA, and Europe.
Speaking about the unveiling of RXT 21, Dr. Shyam Vasudeva Rao, Founder and Director of Renalyx Health Systems, said, “Our state-of-the-art hemodialysis machine will revolutionize kidney care by making dialysis facilities affordable and accessible, thereby strengthening the country’s kidney healthcare infrastructure. By bringing dialysis services closer to patients’ homes, RXT 21 will aid in treating the growing burden of chronic diseases like Chronic Kidney Disease (CKD) and help End-Stage Renal Disease (ESRD) patients. Our indigenously developed hemodialysis machine will play a transformative role in reducing the cost of dialysis, leading to better and more effective healthcare outcomes. Moving forward, we plan to increase our production capacity and reduce the total cost of ownership of RXT 21 by 40 percent compared to imported machines.”
He further added that they plan to develop a wider range of technologically advanced machines, including a home dialysis model, in the next three years. “In line with the government’s ‘Make in India – Make for the World’ vision, our goal is to export our machines to various countries to significantly impact global kidney care infrastructure. We have set an ambitious target of becoming one of the world’s leading manufacturers and exporters in the next five years.”
Indian CDSCO machine approval is in its final stages and is expected by July 2025, while the US FDA approval process is ongoing in the USA and is expected to be completed by March 2026.
The Renalyx – RXT 21 machine is equipped with advanced features such as an integrated Nephrology Information System (NIS) on the cloud, AI-based smart algorithms, Electronic Medical Records (EMR) integration, remote diagnostics and alerts via real-time telemetry, advanced image processing, continuous performance monitoring, and Internet of Medical Things (IoMT) capabilities for clinical monitoring. These advanced features will allow doctors to remotely access patients’ EMRs, current dialysis machine settings, and critical event history without delay, enabling them to effectively advise on necessary treatment and care.
Renalyx plans to install RXT 21 in Primary Health Centers (PHCs), Community Health Centers (CHCs), private dialysis centers, and hospitals to make kidney care accessible to a large number of people. To ensure smooth implementation of the smart machine, the company has established local service teams and developed training programs for technicians. The company, along with its partners, will also establish franchise centers across India. The company, in collaboration with its partners, will establish franchise centers throughout India and in international markets.
Additionally, Renalyx has granted a manufacturing license to Bharat Electronics Limited (BEL) to produce 6,000 units of Renalyx – RXT 17 over the next three years. Renalyx – RXT 17 is a previously launched dialysis machine by Renalyx that comes with standard features and facilities. With Renalyx – RXT 21 and RXT 17, Renalyx aims to play its part in making dialysis services affordable and accessible in rural areas due to the repetitive nature of the treatment. According to data from the Pradhan Mantri National Dialysis Program (PMNDP), approximately 2.20 lakh new End-Stage Renal Disease (ESRD) patients are registered in India annually, creating an additional demand for 3.4 crore dialysis sessions every year.
